Notable Price Action: Today Supernus Pharmaceuticals Inc Stock Crashes

Notable Price Action: Today Supernus Pharmaceuticals Inc Stock Crashes

The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) is a huge mover today! The stock decreased 3.96% or $0.98 during the last trading session, hitting $23.75. About 1.05 million shares traded hands or 55.35% up from the average. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has risen 82.97% since March 1, 2016 and is uptrending. It has outperformed by 70.76% the S&P500.
The move comes after 8 months negative chart setup for the $1.18B company. It was reported on Oct, 4 by Barchart.com. We have $21.85 PT which if reached, will make NASDAQ:SUPN worth $94.40M less.

Analysts await Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to report earnings on November, 1. They expect $0.21 EPS, up 162.50% or $0.13 from last year’s $0.08 per share. SUPN’s profit will be $10.43M for 28.27 P/E if the $0.21 EPS becomes a reality. After $0.18 actual EPS reported by Supernus Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 16.67% EPS growth.

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Ratings Coverage

Out of 3 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Supernus Pharmaceuticals has been the topic of 6 analyst reports since August 26, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Thursday, August 4 by Jefferies. The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has “Market Perform” rating given on Monday, July 18 by Northland Capital. Northland Capital initiated Supernus Pharmaceuticals Inc (NASDAQ:SUPN) on Wednesday, October 28 with “Outperform” rating. The rating was downgraded by Piper Jaffray to “Neutral” on Monday, July 18. The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) earned “Hold” rating by Zacks on Wednesday, August 26. Northland Capital maintained the shares of SUPN in a report on Thursday, November 5 with “Outperform” rating.

According to Zacks Investment Research, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.”

Insitutional Activity: The institutional sentiment increased to 1.26 in 2016 Q2. Its up 0.11, from 1.15 in 2016Q1. The ratio improved, as 27 funds sold all Supernus Pharmaceuticals Inc shares owned while 62 reduced positions. 25 funds bought stakes while 87 increased positions. They now own 45.62 million shares or 4.54% more from 43.64 million shares in 2016Q1.
Scout last reported 172,300 shares in the company. Fmr Limited Liability Corp accumulated 1.07M shares or 0% of the stock. The Manitoba – Canada-based Great West Life Assurance Can has invested 0% in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Rhumbline Advisers accumulated 51,383 shares or 0% of the stock. Mufg Americas Holding Corporation has invested 0% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Nationwide Fund Advisors last reported 101,448 shares in the company. Paradigm Asset Mgmt Limited Liability Company has invested 0% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Ngam Advsr Limited Partnership holds 0.01% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 23,701 shares. California State Teachers Retirement Systems holds 0% or 98,380 shares in its portfolio. Dupont Mgmt has invested 0.04% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Moreover, Mutual Of America Capital Mngmt Ltd Llc has 0.24% invested in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 547,018 shares. Schwab Charles Investment has invested 0% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Gsa Capital Prtn Llp holds 210,429 shares or 0.24% of its portfolio. Price T Rowe Assocs Md accumulated 48,860 shares or 0% of the stock. Credit Suisse Ag has 90,151 shares for 0% of their US portfolio.

Insider Transactions: Since April 11, 2016, the stock had 0 insider purchases, and 2 selling transactions for $557,228 net activity. 2,000 shares were sold by PATRICK GREGORY S, worth $50,000 on Friday, September 16. 30,762 shares were sold by Bhatt Padmanabh P., worth $507,228.

More recent Supernus Pharmaceuticals Inc (NASDAQ:SUPN) news were published by: Fool.com which released: “Supernus Pharmaceuticals Is Dropping — Is It a Buy?” on November 12, 2015. Also Prnewswire.com published the news titled: “Supernus Pharmaceuticals Founder and CEO Jack Khattar joins scPharmaceuticals …” on July 12, 2016. Reuters.com‘s news article titled: “BRIEF-Supernus pharmaceuticals Inc says FY 2016 net product sales will rem…” with publication date: August 02, 2016 was also an interesting one.

SUPN Company Profile

Supernus Pharmaceuticals, Inc. (Supernus), incorporated on March 30, 2005, is a pharmaceutical firm focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Firm offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It is also engaged in developing multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). The Company’s psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is also developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. The Firm markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment